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Background: To report on establishment of workflow and clinical results of particle therapy at the Heidelberg Ion
Therapy Center.
Materials and methods: We treated 36 pediatric patients (aged 21 or younger) with particle therapy at HIT.
Median age was 12 years (range 2-21 years), five patients (14%) were younger than 5 years of age. Indications
included pilocytic astrocytoma, parameningeal and orbital rhabdomyosarcoma, skull base and cervical chordoma,
osteosarcoma and adenoid-cystic carcinoma (ACC), as well as one patient with an angiofibroma of the
nasopharynx. For the treatment of small children, an anesthesia unit at HIT was established in cooperation with the
Department of Anesthesiology.
Results: Treatment concepts depended on tumor type, staging, age of the patient, as well as availability of specific
study protocols. In all patients, particle radiotherapy was well tolerated and no interruptions due to toxicity had to
be undertaken. During follow-up, only mild toxicites were observed. Only one patient died of tumor progression:
Carbon ion radiotherapy was performed as an individual treatment approach in a child with a skull base recurrence
of the previously irradiated rhabdomyosarcoma. Besides this patient, tumor recurrence was observed in two
additional patients.
Conclusion: Clinical protocols have been generated to evaluate the real potential of particle therapy, also with
respect to carbon ions in distinct pediatric patient populations. The strong cooperation between the pediatric
department and the department of radiation oncology enable an interdisciplinary treatment and stream-lined
workflow and acceptance of the treatment for the patients and their parents.
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In pediatric oncology, most treatment concepts in the
21st century are of curative intent, aiming at long-term
overall survival. With continuous increase in tumor con-
trol and cure, also side effects of the treatments, espe-
cially long-term side effects, have moved even more into
focus. With respect to radiotherapy, sparing of normal* Correspondence: stephanie.combs@med.uni-heidelberg.de
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reproduction in any medium, provided the ortissue and reduction of integral dose is the most effective
means to prevent treatment-related side effects. Over
the last decades, advances in radiation oncology from
conventional 2D- to 3D-radiation therapy, to the estab-
lishment of high-precision stereotactic radiotherapy and
subsequently intensity-modulated radiotherapy (IMRT)
have continuously enabled the radiation oncologist to
deliver higher local doses even to complex target
volumes while sparing surrounding organs at risk
(OAR). However, intermediate and low doses of radi-
ation remain to be applied. One way of reducing integralLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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particle therapy, due to the physical properties of ion
beams [1,2]).
The distinct physical characteristics of a particle beams
potentially offer clinical benefit especially in pediatric
oncology: In the entry channel of the beam almost no
energy is deposited, while a high local dose deposition,
the Bragg Peak, can be guided by energy-variation of the
beam, into the defined target volume. Dose distributions
are characterized by a steep dose-fall-off at the field bor-
ders, and the integral dose can be reduced significantly.
Therefore, proton radiotherapy has a central role in
pediatric oncology, and should be applied when avail-
able. In clinically active proton centers such as the Paul-
Scherrer-Institute (PSI) in Villigen, Switzerland, at
Francis H. Burr proton center in Boston, or at MD An-
derson Cancer Center in Houston, proton radiotherapy
has been established in clinical routine for paediatric
patients. Clinical results in different tumor entities such
as rhabdomyosarcoma, ependymoma or medulloblas-
toma have shown very low toxicity and promising out-
come [3-12]. Moreover, comparative analyses with
photon treatment have shown that reduction of integral
dose may lead to a significant decrease in side effects,
especially with respect to secondary malignancies in
pediatric patients treated with proton radiotherapy [13].
However, until now no real long-term data, especially no
randomized comparisons of high-end photons and pro-
tons are available.
Carbon ions, additionally to the physical benefits of par-
ticle beams, offer a higher relative biological effectiveness
(RBE) which can be exploited also in pediatric oncology
for very radioresistant tumors, such as osteosarcomsas,
difficult to treat with low-LET radiotherapy [14].
To effectively compare particle therapy with advanced
photon techniques, multiple field treatment planning as
well as active beam application is required. Modern
particle therapy centers are equipped with active beam
delivery, as well as with gantries to allow for variable
beam positions. At the Heidelberg Ion Therapy (HIT)
center, active beam delivery using the rasterscanning
technique is available for particle therapy. Moreover,
the center is equipped with two horizontal treatment
rooms, as well as an ion gantry for carbon and proton
treatments [14].
Since November 2009, HIT is treating patients within
clinical routine offering carbon and proton radiotherapy
for adults and pediatric patients alike. The close colla-
borations with the Department of Pediatric Hematology
and Oncology and the Department of Anesthesiology
enable a strong interdisciplinary treatment of children as
in- or outpatients.
In the present work we report our initial experience of
particle therapy in pediatric patients with and withoutanesthesia focusing on the establishment of workflow,




From January 2009 to November 2011, we treated 36
pediatric patients (aged 21 or younger) with particle
therapy at HIT. All patients were seen and the treatment
concepts were discussed in an interdisciplinary team.
This project was performed in accordance with institu-
tional ethical policies. All data was collected from our
institutional patient database and tumor registry. They
were collected anonymously using a uniform retrieval
code for data acquisition.
Median age was 12 years (range 2-21 years), five
patients (14%) were younger than 5 years of age. Indica-
tions included pilocytic astrocytoma, parameningeal and
orbital rhabdomyosarcoma, skull base and cervical chor-
doma, osteosarcoma and adenoid-cystic carcinoma
(ACC), as well as one patient with an angiofibroma of
the nasopharynx. In all but one patients radiotherapy
was performed as primary radiation treatment. Only one
patient with a recurrent rhabdomyosarcoma (RMS) of
the skull base was treated as re-irradiation. Patients’
characteristics are summarized in Table 1.
Treatment planning
Particle therapy was applied using the intensity modu-
lated rasterscanning technique with the horizontal
beamline. Sixteen patients were treated with protons
(44%), and 13 patients (36%) were treated with carbon
ions (C12). C12 was mostly applied for young adults
with skull base tumors, and protons were mostly used
for pediatric patients. In 7 patients (20%) with difficult-
to control tumors (glioblastoma, osteosarcoma and
adenoid-cystic-carcinoma (ACC)) requiring high local
doses, particle therapy as a boost treatment to the
macroscopic tumor was combined with photon IMRT.
Treatment planning as well as radiation therapy was
performed in individual fixation devices manufactured
individually for each patient. For brain and skull base
tumors, either Scotch Cast™ or thermoplastic mask sys-
tems were used allowing an overall repositioning accur-
acy of 1-2 mm. For thermoplastic mask systems, patient
positioning was conducted with the laser system in the
treatment room using Beekley-Spots® on the mask or
with three target points tattooed and marked with metal
fiducials during the planning CT scan. For Scotch Cast™
Cast masks, patient setup was performed using stereo-
tactic setup. Pelvic tumors were immobilized using indi-
vidual vacuum bags or a combination of knee and foot
rests. Target volume definition was based on CT- and
MR-Imaging; amino-acid PET or FDG-PET was used for
Table 1 Patients’ characteristics of 36 children and young
adults treated with protons and carbon ions at the
Heidelberg Ion Therapy Center (HIT)
Histology N (%)
primary brain tumors 10 (28%)
pilocytic astrocytoma n = 7
glioblastoma n = 1
ATRT n = 1
PNET n = 1
chordoma/chondrosarcoma 10 (28%)
skull base chordoma n = 7
skull base chondrosarcoma n = 3
osteosarcoma 3 (8%)
Skull base n = 2
pelvic n = 1
rhabdomyosarcoma 4 (11%)
ACC 3 (8%)










Carbon ions 13 (36%)
Photon + Carbon Ion Boost 6 (+ 1 Proton Boost) (20%)
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the respective clinical situation. Depending on the tumor
entity and tumor site as well as the postoperative situ-
ation, we defined target volumes according to ICRU cri-
teria including a gross tumor volume (GTV), clinical
target volume (CTV) as well as a planning target volume
(PTV).
Target volume definition is conducted on every slice of
the three-dimensional data cube using the Siemens Dosi-
metrist and Oncologist software tools (Siemens, Erlangen,
Germany). For treatment planning, the system “Syngo
PT Planning” developed by Siemens Oncology Care Sys-
tems (OCS, Erlangen, Germany) was used, offering all
modern aspects of 3D treatment planning, which was
specifically developed for planning of scanned proton
and ion beams. It includes three-dimensional treatment
planning based on biological plan optimization using the
approach of the Local Effect Model (LEM). The LEM is a
generic model allowing for RBE-calculation in different
tissue types and for selected endpoints, which wasvalidated in various preclinical calculations and by the
treatment of over 450 patients at the Gesellschaft für
Schwerionenforschung (GSI) [15]. The optimization of
the scan control parameters for the raster scanning tech-
nique within the treatment planning system (TPS) is
done with respect to the biological effective dose of the
particles. A fixed value for the relative biological effect-
iveness (RBE) of 1.1 is used clinically for proton treat-
ments. For carbon ions, the optimization is based on the
LEM model with tumor- and normal-tissue specific α/β
values.
Patient positioning
To validate patient positioning prior to each fraction of
particle therapy using an orthogonal X-ray imaging sys-
tem, correlation of planning CT DRRs with the orthog-
onal X-ray focusing mainly on bony landmarks was used
for position corrections. This registration process and
the subsequent performance of the calculated correction
vector were supervised by a radiation oncologist to-
gether with the radiation therapist. Position correction
was performed using re-positioning of the treatment
couch as well as using the pitch-and-roll feature of the
robotic table system in some patients.
Anesthesia
For the treatment of small children, an anesthesia unit at
HIT was established in cooperation with the Department
of Anesthesiology. For this purpose, a dedicated anesthesia
room was built equipped with the required instruments
and medication. A transportable anesthesia system (Drae-
ger, Lübeck, Germany) was installed on the treatment
table in the particle therapy treatment room (Figure 1). A
risk analysis has been performed according to the medical
device directive. For observation of vital parameters, rele-
vant information is transmitted into the treatment control
rooms via realtime datalines for continuous monitoring
of the small children. A specialized team of pediatric
anaesthesiologists performs anesthesia for each treat-
ment fraction. Application of anesthesia is performed in
the treatment room, and dedicated data lines ensure
secure observation of vital parameters during irradiation.
Follow-up visits
All patients were seen for regular follow-up visits initially
4-6 weeks after completion of radiotherapy, thereafter in
2-3 months intervals or as required clinically. Patients
were seen by the Department of Pediatric Hematology
and Oncology as well as the Radiation Oncology Depart-
ment. No patient was lost to follow-up.
Tumor control was documented with imaging on each
follow-up visit, depending on the tumor type. Additional
examinations including endocrinological follow-up were
scheduled as required.
Figure 1 Clinical workflow for treatment under anesthesia in cooperation with the Department of Anesthesiology (A). A mobile
anesthesia device was connected to the observation console of the radiation therapy treatment room; continuous monitoring of the patient was
possible during patient setup and irradiation from outside the treatment room (B).
Combs et al. Radiation Oncology 2012, 7:170 Page 4 of 9
http://www.ro-journal.com/content/7/1/170Treatment-related side effects were documented
according to the Common Terminology Criteria for
Adverse Events (CTCAE) Version 4.1.
Results
Treatment concepts
Treatment concepts depended on tumor type, staging,
age of the patient, as well as availability of specific study
protocols. In general, pediatric patients are treated
within study protocols of the German Society for
Pediatric Hematology and Oncology, and target volumes
as well as dose prescription were performed accordingly.
These were dependent on histology and location, e.g. for
low-grade gliomas, a dose of 50.4 Gy - 54 Gy E was
applied in 1.8 Gy fractions using protons, and for the
orbital rhabdomyosarcoma a median total dose of
52.2 Gy in single fractions of 1.8 Gy was applied using
protons.
For ACC, which is rarely seen in pediatric patients
and young adults, the treatment concept was based on
the established regimen for adult patients, including
photon radiotherapy and a carbon ion boost to the
primary tumor region after incomplete resection [16].
In general photon radiotherapy is given to the areas of
microscopic spread up to 50 Gy, and the carbon boost
is applied up to 18 Gy E; in a most recent trial, the
boost escalation to 24 Gy E was evaluated, the trial
has finished recruitment, and early data showed overall
tolerability [17]. Specific protocols at the Heidelberg
Center have been established for certain difficult to
treat tumor entities, including osteosarcoma and glio-
blastoma [18]. For glioblastoma, the CLEOPATRA-
protocol evaluates a carbon ion boost to the macroscopic
tumor identified by amino-acid-PET and T1-weighted
contrast-enhancing MRI [19]. Photon radiotherapy is
applied to the resection cavitiy and T2-Hyperintense
region with a total dose of 50 Gy E in 2 Gy E frac-
tions, and the carbon ion boost in the experimental armis applied up to 18 Gy E in 3 Gy E fractions. In the con-
trol arm, proton radiotherapy is applied up to the stand-
ard dose of 60 Gy E in 5 fractions à 2 Gy E after the
photon part.
For patients with osteosarcoma, a carbon ion boost to
the macroscopic tumor after proton radiotherapy is eval-
uated within a single-armed phase II trial [20]. Chemo-
therapy is added according to the most recent
multimodality protocols in this indication (COSS/EUR-
AMOS). For chordoma and chondrosarcoma patients,
target volume definition is comparable to treatment con-
cepts in the adult population [21,22].
Tolerability of treatment
In all patients, particle treatment was well tolerated
and no interruptions due to toxicity had to be under-
taken; planned radiation series could be completed ap-
plying the prescribed doses. Toleration of positioning
devices worked well in most patients, for smaller chil-
dren without anesthesia training sessions to tolerate
mask fixations were held. Four patients aged 4 years
and younger were treated with anesthesia. One patient
suffered from a local atypical rhabdoidtumor (ATRT)
of the brain stem, one patient was diagnosed with an
infratentorial pilocytic astrocytoma, one with a large
optic glioma, and one Ewing’s sarcoma of the right
maxillofacial region.
The median follow-up time was 9 months (range 1-
23 months). No patient was lost to follow-up.
During follow-up, only mild toxicites were observed
including hair loss in patients with superficial lesions.
Two patients with base-of-skull tumors developed
middle-ear effusion towards the end of treatment. Six
patients developed mucositis CTCAE Grade 1-2;
patients suffered from large base-of-skull tumors and
ACCs, as well as one patient with an oropharyngeal
synovial sarcoma and one large rhabdomyosarcoma.
No severe acute effects were observed. Specific region-
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bital rhabdomyosarcoma treated with protons showing
a mild conjunctivitis to the end of treatment. The
treatment plan is shown in Figure 2.
A 16-years-old male patient treated for a rhabdomyo-
sarcoma of the skull base with positive cervical lymph
nodes was treated with hyperfractionated-accelerated
proton radiotherapy according to the soft tissue sarcoma
study protocol (CWS) up to a total dose of 51.2 Gy E in
single doses of 1.6 Gy E, twice daily. The patient devel-
oped mucositis CTC Grad II-III with difficulty swallow-
ing during treatment, which resolved completely until
the first follow-up visit. However, this patient developed
an early recurrence with distant meningeal spread along
the craniospinal axis, however, the local primary tumor
region remains stable.
During follow-up, hyperpigmentation in the RT por-
tals were observed in two patients, one with an orbital
rhabdomysarcoma, and one with a sarcoma of the
larynx.Figure 2 Two-field proton treatment of a 5 years-old child with an orTreatment response and local control
During follow-up, only one patient died of tumor pro-
gression: Carbon ion radiotherapy was performed as an
individual treatment approach in a child with a skull
base recurrence of the previously irradiated rhabdomyo-
sarcoma. Local tumor recurrence was observed at first
follow-up 4 weeks after the end of treatment, and pallia-
tive care was decided on an interdisciplinary consensus.
Besides this patient, tumor recurrence was observed in
two additional patients: A 18 years old female with a
glioblastoma treated with a carbon ion boost developed
local tumor recurrence 13 months after primary diagno-
sis. As salvage treatment, chemotherapy was intensified.
Another 16 years old boy treated for a rhabdomyosar-
coma of the skull base with positive cervical lymph
nodes developed progression as meningeal spread along
the craniospinal axis with tumor cells in the craniospinal
fluid (CSF) 6 months after proton treatment. Salvage
treatment consisted of chemotherapy, as well as irradi-
ation of the craniospinal axis avoiding the previouslybital rhabdomyosarcoma.
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to 50 Gy to the visible macroscopic lesions, with helical
tomotherapy.
All other patients remained stable during follow-up
with no signs of clinical or imaging defined tumor pro-
gression. Tumor response was observed in several
patients depending on histology, most predominantly in
ACC, sarcoma and primary brain tumor patients. Clinical
response was also observed in patients with skull base
lesions including resolution of occulomotor and abdu-
cens pareses in 2 patients. Pain in the sacral region
improved significantly after carbon ion radiotherapy for a
sacral osterosarcoma, and hemipareses improved correl-
ating with imaging-response in a glioblastoma patient.
A four-year old child with an infratentorial pilocytic
astrocytoma was treated for tumor progression with
anesthesia, during follow-up, the lesion showed a signifi-
cant reduction in size, as well as a clear response with
respect to contrast-enhancement which almost resolved
completely (Figure 3). The patient treated for an orbital
rhabdomyosarcoma with severe exophthalmia prior toFigure 3 Treatment of a patient with an infratentorial pilocitic astrocy
protons, 2 fields, total dose of 54 Gy E in single doses of 1.8 Gy E (E-H), andtreatment demonstrated significant reduction in tumor
volume during follow-up. Clinically, exophthalmia
resolved almost completely, and only a slight hyperpig-
mentation in the area of the treatment portals remained
during follow-up (Figure 4).
Discussion
Particle therapy for the curative treatment of children
and young adults requires special demands on all ranks:
Indication for treatment must be decided in an interdis-
ciplinary setting, keeping in mind several important fac-
tors such as patient age, tumor type, staging and risk
group, existing treatment concepts and running study
protocols, as well as the special care necessary for small
children requiring anesthesia for treatment. A strong
focus must be set on target volume definition, delineation
of organs at risk (OAR), choice of the optimal beam
angles and dose distribution aiming at a reduction of
dose to normal tissue. The reduction of integral dose is a
main concern in pediatric radiation oncology, and the
physical properties of ion beams offer a benefit comparedtoma. Imaging for Treatment planning (A-D), treatment plan for
imaging response 3 months after treatment (I-L).
Figure 4 Imaging response of a 5 years-old child with an orbital rhabdomyosarcoma (plan shown Figure 4). Inital imaging for treatment
planning (A;B), Follow-up imaging 6 months after treatment; imaging showed a significant reduction in contrast enhancement with an overall
reduction of the lesion in diameter.
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dose deposition in the entry channel of the beam, and
the high local dose deposition within the Bragg peak.
Clinical evaluation and long-term data are currently
being generated within several clinical protocols.
At HIT, treatment of pediatric patients with different
indications was established since the beginning of pa-
tient treatment in 2009. Since then, 36 patients with dif-
ferent tumor entities were treated with proton and
carbon ion radiotherapy. A streamlined clinical workflow
for even very young children in anesthesia was estab-
lished by a close collaboration with a dedicated team of
anaesthesiologists for pediatric anesthesia. The strong
collaboration with the neighboring departments of
neurosurgery and pediatric oncology enable efficient and
patient-oriented medical care. In all patients, few toxici-
ties were observed, which were only mild and related to
the size and anatomical lesion of the patients. Especially,
frequent side effects such as hair loss in patients treated
for brain tumors can be reduced significantly, depending
on the location of the lesion. No severe acute or long-
term side effects could be documented. Imaging re-
sponse was observed in a number of patients, and all
patients despite three remained stable during follow-up.
Recurrences occurred in three patients, one child treatedfor a recurrence of a skull base rhabdomyosarcoma, and
another patient developed meningeal spread along the
craniospinal axis based on a cervical rhabdomyosar-
coma, and in one patients with a glioblastoma. The
safety and efficacy of proton and carbon ion treatments
delivered by active rasterscanning could therefore be
demonstrated.
The potential benefit of particle therapy for pediatric
patients is the possibility to reduce integral dose, and
thus reduce the risk for radiation-induced side effects,
such as secondary malignancies. Is has been shown that
taking into account several risk estimates, particle treat-
ments compare favorably to photon treatments, espe-
cially when using beam scanning compared to beam
scattering [23,24]. Several proton centers have reported
excellent clinical outcome in various tumor entities:
At MGH in Boston, the treatment of patients with
parameningeal rhabdomyosarcoma was studied based on
elaborate treatment planning comparisons, evaluating
the optimal treatment available [24]; In a group of 17
children treated with protons with a median age of
3.4 years (range, 0.4-17.6), a median dose of 50.4 Gy E
was applied [3]. After a median follow-up time of 5 years,
59% remained failure-free, and overall survival was 64%.
Late effects related to proton radiotherapy in the 10
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height in three patients, endocrinopathies (n = 2), mild
facial hypoplasia (n = 7), failure of permanent tooth
eruption (n = 3), dental caries (n = 5), and chronic nasal/
sinus congestion in two patients. For Ewing’s sarcoma,
as well, only mild side effects were observed in a group
of 30 children, with tumors originating from various
anatomical regions [25]. After a median proton dose of
54 Gy E, 3-years event-free survival rate was 60%, with
local control and overall survival at 86% and 89%. Side
effects included mostly mild reactions of the skin, des-
pite four hematologic malignancies often observed after
topoisomerase and anthacycline chemotherapy. For pri-
mary brain tumors, such as ependymomas, proton radio-
therapy has shown convincing initial clinical results in
17 patients after a median follow-up of 26 months. Local
control was 86%, and overall survival was 89%, with the
extent of surgery being the most prominent prognostic
factor [8]. Other studies have reported similarly convin-
cing results for germ cell tumors, craniopharyngioma,
bladder sarcoma as well as skull base tumors [4-6,26,27].
To fully evaluate the long-term potential of particle
therapy in pediatric patients requires much longer follow-
up, which is the main downside in all current publications
on particle therapy. Especially to completely understand
the risk profile towards reduction of secondary malignan-
cies, longer observation is required. Comparative data of
protons and photons have suggested such a potential ef-
fect [28]. With respect to carbon ion radiotherapy and the
distinct radiobiological properties, clinical implementation
in pediatric patients should be applied cautiously due to a
possible higher risk for treatment-induced secondary ma-
lignancies [29]. Therefore, this modality should be with-
held for clinical situations in which the tumor is difficult
to control with conventional low-LET-radiation, such as
osteosarcoma. Therefore, in such a patient group the
evaluation of carbon ion radiotherapy also in pediatric
patients can be justified [20].In conclusion
The largest benefit of proton radiotherapy can be
expected in the pediatric population. Therefore, estab-
lishment of particle therapy also for children and young
adults was a high priority at the Heidelberg Center.
Treatment of also very small children under anesthesia is
possible. In general pediatric patients are treated with
protons, except for specific indications within clinical
protocols, e.g. osteosarcoma. Clinical protocols have
been generated to evaluate the real potential of particle
therapy, also with respect to carbon ions in distinct
pediatric patient populations. The strong cooperation be-
tween the pediatric department and the department of
radiation oncology enable an interdisciplinary treatmentand stream-lined workflow and acceptance of the treat-
ment for the patients and their parents.
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